Ajanta Pharma has published a strategic outlook identifying five key trends expected to define the future of obesity care in India over the next decade.
The Mumbai-based pharmaceutical company released the perspective on July 9, positioning itself at the forefront of the expanding metabolic health market in South Asia.
The publication comes as global investors scrutinize the sustainability of the weight-loss drug boom.
Recent analysis has highlighted a potential 'bubble effect' within the pharmaceutical sector, driven by the rapid adoption of treatments such as Wegovy.
While demand surges, questions regarding long-term pricing power and market saturation persist among institutional investors.
Ajanta Pharma’s framework suggests that the Indian market is approaching a pivotal moment, with increasing awareness and accessibility driving structural changes in patient care.